1290136-89-8Relevant academic research and scientific papers
CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS
-
Page/Page column 239, (2021/04/10)
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
QUINAZOLINONE COMPOUNDS AND RELATED COMPOUNDS
-
Paragraph 0165-0166, (2021/08/27)
Disclosed are substituted quinazolinone compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions to treat diseases, disorders, or conditions such as those relating to unregulated protein functi
BCL-2 INHIBITORS
-
Page/Page column 204, (2020/03/15)
The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
BCL-2 INHIBITORS
-
Page/Page column 54, (2017/08/21)
The disclosure includes compounds of Formula (I) Formula (I) wherein W, R1, R2, R3, R4, R5, R6, rn, n, L, and Z1, are defined herein. Also disclosed is a method for treating a neoplastic disease and autoimmune disease with these compounds.
INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
Page/Page column 89, (2013/04/25)
The present teaching provide indazole compounds represented by Structural Formulae (I) or (I') or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as T
2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME
-
Page/Page column 14, (2011/05/03)
The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): wherein R1, R2 and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.
